A multiomic analysis of samples from newly diagnosed multiple myeloma patients treated with isatuximab, carfilzomib, lenalidomide and dexamethasone found that baseline genomic, transcriptomic and epigenetic features are associated with minimal residual disease status after induc…
Baseline Genomic and Epigenetic Features Linked to MRD Status in Multiple Myeloma Quadruplet Therapy
A multiomic analysis of samples from newly diagnosed multiple myeloma patients treated with isatuximab, carfilzomib, lenalidomide and dexamethasone found that baseline genomic, transcriptomic and epigenetic features are associated with minimal residual disease status after induction therapy.
Biopsy · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.